Cencora, Inc. (NYSE:COR) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas cut its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 72.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 33,871 shares of the company's stock after selling 87,769 shares during the quarter. Teacher Retirement System of Texas' holdings in Cencora were worth $9,419,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in COR. Fisher Asset Management LLC grew its stake in shares of Cencora by 17.7% during the 4th quarter. Fisher Asset Management LLC now owns 1,091 shares of the company's stock worth $245,000 after purchasing an additional 164 shares during the period. Jones Financial Companies Lllp grew its stake in Cencora by 212.4% in the 4th quarter. Jones Financial Companies Lllp now owns 2,390 shares of the company's stock valued at $537,000 after acquiring an additional 1,625 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Cencora in the 4th quarter valued at about $30,000. Victory Capital Management Inc. grew its stake in Cencora by 25.2% in the 4th quarter. Victory Capital Management Inc. now owns 255,425 shares of the company's stock valued at $57,389,000 after acquiring an additional 51,345 shares during the last quarter. Finally, Assetmark Inc. grew its stake in Cencora by 1,165.7% in the 4th quarter. Assetmark Inc. now owns 32,097 shares of the company's stock valued at $7,212,000 after acquiring an additional 29,561 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman owned 311,913 shares in the company, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer owned 47,582 shares in the company, valued at $13,766,900.06. The trade was a 9.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,127 shares of company stock worth $9,812,296 in the last 90 days. 10.80% of the stock is currently owned by insiders.

Cencora Trading Up 1.7%

Shares of COR stock opened at $296.23 on Friday. The firm has a market cap of $57.42 billion, a P/E ratio of 34.37, a PEG ratio of 1.47 and a beta of 0.57. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. The firm's 50-day simple moving average is $291.12 and its 200-day simple moving average is $267.51.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $3.80 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.74%. Cencora's payout ratio is 25.52%.

Analyst Ratings Changes

COR has been the topic of a number of research reports. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Citigroup upped their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Jefferies Financial Group upped their target price on shares of Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a report on Monday, June 30th. UBS Group upped their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Finally, Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $306.33.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.